Clinical trial NCT02694952: Non-inferiority Trial of Two Snake Antivenoms in CAR (PAVES)
Official title: Randomized, Double-blind, Non-inferiority Trial of Two Antivenoms for the Treatment of Snakebite With Envenoming
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Snake Bites
Lead sponsor: Epicentre
Sponsor class: OTHER
Collaborators: name: Medecins Sans Frontieres, Netherlands
First posted: 2016-03-01
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Interventional, individually randomized, double (e.g. investigator and participant) blinded, parallel two-arm, non-inferiority trial to assess the efficacy of EchiTabPlus-ICP compared to FAV-Africa for the treatment of snakebite with envenoming.

Detailed description: The study is designed as a randomized, double-blind, non-inferiority trial among patients suffering envenoming following snakebite in Paoua, Central African Republic. The primary aim of the study is to assess the non-inferiority of EchiTabPlus-ICP compared to FAV-Africa, at preventing a composite primary endpoint consisting of death from any cause, need for blood transfusion or need for a third dose of antivenom.

A total of 196 patients will be individually randomized in a 1:1 ratio to receive FAV-Africa or EchiTabPlus-ICP.

The first dose of intervention antivenom will be administered at study enrollment, and the need for further doses will be judged by clinical exam and the 20 minute WBCT, following the protocol. All other necessary medical care will be provided as per routine in the Paoua Prefectural Hospital. Study followup and surveillance for adverse events and serious adverse events will continue until 28 days after the initial dose of antivenom.

Unique identification numbers will be allocated by an individual independent of the study team using a computer-generated random number list using permuted blocks of random sizes. Block sizes will not be disclosed to reduce predictability of the random sequence and ensure allocation concealment. The Site Principal Investigator who will oversee randomization will be given a set of sequentially numbered silver coated booklets. The Site Principal Investigator will be instructed to assign the next sequential randomization code noted in the booklet to each eligible participant as (s)he is enrolled.

Study antivenoms will be prepared by the unblinded study pharmacist, and will be provided to the clinical staff in identical presentations. Group assignment will remain concealed from study personnel, investigators, and participants for the entire study period. The Data and Safety Monitoring Board (DSMB) will also be masked to the group assignment. The DSMB will remain masked unless otherwise deemed necessary by the DSMB members for any safety related issues. Investigators conducting the final analysis will remain masked to the group assignment until the end of the analysis.

Eligibility criteria: Inclusion Criteria:

* present within 72 hours of snakebite
* have signs and symptoms of grade 2 envenoming (oedema beyond the elbows or knees, bleeding at site of bite, bleeding from the gums or hematuria) or grade 3 envenoming (oedema to the shoulders or hips, or serious bleeding - epistaxis, hemoptysis, gastrointestinal bleeding)
* lack of coagulation of blood at 20 minutes in a dry vacutainer tube (abnormal 20 minute WBCT)

Exclusion Criteria:

* known allergy to horses or heterologous proteins of equine origins
* pregnancy
* have received antivenom since the snakebite

Primary outcomes:
measure: Number of patients needing a third dose of antivenom, needing a blood transfusion, or dying
timeFrame: 28 days after enrolment
Secondary outcomes:
measure: Death from any cause
timeFrame: 28 days after enrolment
measure: Need for blood transfusion
timeFrame: Will be evaluated at 2, 6, 12, and 24 hours after enrolment and at hospital discharge
measure: Need for third dose of antivenom
timeFrame: Will be evaluated at 2, 6, 12, and 24 hours after enrolment and at hospital discharge
measure: Normalization of coagulopathy as measured by the 20 minute whole blood clotting test
timeFrame: Will be evaluated at 2, 6, 12, and 24 hours after enrolment
Other outcomes:
Locations:
Study officials:
affiliation: Epicentre
name: Rebecca Grais, PhD
role: STUDY_DIRECTOR
References: